Autoimmune Technologies - Applied Biomedical Science

Entry-Inhibiting Influenza Drugs
Autoimmune Technologies and Tulane University School of Medicine are working to develop entry-inhibiting influenza drugs based on small peptides. In the in vitro assays run to date, our lead flu peptide drug, FF-3, appears to be extremely effective against subtypes of the influenza A virus which cause seasonal flu as well as against the dangerous H5N1 influenza A subtype. It is also highly effective against influenza B. In initial in vivo tests, FF-3 demonstrated the ability to completely eliminate all signs of seasonal influenza A in most of the animals tested and to block transmission of this seasonal flu among infected animals and their uninfected cagemates.

This material is not intended to take the place of a physician's advice.


Web site by: New Orleans Web Design